South Dakota Investment Council Raises Position in Hologic, Inc. (NASDAQ:HOLX)

South Dakota Investment Council grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 212.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,500 shares of the medical equipment provider's stock after acquiring an additional 5,100 shares during the period. South Dakota Investment Council's holdings in Hologic were worth $463,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Commonwealth Equity Services LLC lifted its stake in shares of Hologic by 1.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 61,958 shares of the medical equipment provider's stock valued at $4,467,000 after buying an additional 735 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Hologic by 47.5% during the 4th quarter. TD Private Client Wealth LLC now owns 7,115 shares of the medical equipment provider's stock valued at $513,000 after buying an additional 2,290 shares in the last quarter. Mizuho Securities USA LLC lifted its stake in shares of Hologic by 46.2% during the 4th quarter. Mizuho Securities USA LLC now owns 22,014 shares of the medical equipment provider's stock valued at $1,587,000 after buying an additional 6,952 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Hologic by 14.1% during the 4th quarter. American Century Companies Inc. now owns 1,274,067 shares of the medical equipment provider's stock valued at $91,848,000 after buying an additional 157,731 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Hologic during the 4th quarter valued at approximately $19,891,000. 94.73% of the stock is owned by institutional investors.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.88% of the company's stock.

Hologic Trading Up 0.4%

Hologic stock traded up $0.27 during trading hours on Friday, reaching $66.37. The stock had a trading volume of 158,208 shares, compared to its average volume of 2,897,313. The stock has a market cap of $14.79 billion, a PE ratio of 28.00, a PEG ratio of 2.42 and a beta of 0.55. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The company has a fifty day simple moving average of $63.14 and a 200-day simple moving average of $63.04.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.03 EPS. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HOLX. Morgan Stanley cut their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and raised their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Raymond James Financial reissued an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Finally, Stephens cut their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $77.33.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.